NCT06552858Not yet recruitingPhase 2
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer: a Phase II Clinical Study
Source: ClinicalTrials.gov · Last updated 14 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Aug 2024
- Start date
- 1 Sept 2024
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Fudan University
- Diseases
- Ovarian cancer
- NCT number
- NCT06552858
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 1 Sept 2024 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receipt of any other investigational medicinal product within the last 30 days before randomization.
Other illness
- Any uncontrolled medical condition that may put the patient at high risk during treatment .
- Patients with ovarian cancer excluded by pathological or clinical diagnosis;
Other
- Physical intolerance patients;
- Patients who are unwilling to participate in the clinical trial.
Who the study is looking for
- Age≥18 years old;
- Sign the informed consent form;
- Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer.
- Tumor recurrence or progression within 6 months after using platinum-based drugs;
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan university shanghai cancer center, Deparment of gynecologic oncology Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.